Abstract:Background Drug-eluting stents (DES) have been shown to significantly reduce clinical events and angiographic restenosis in the treatment of coronary artery disease (CAD). This study was conducted to assess the long-term efficacy and safety of the polymer-based sirolimus-eluting cobalt-chromium Firebird 2 (TM) stents in the treatment of patients with CAD.Methods This first-in-man study using the Firebird 2 (TM) stent is a prospective, historically-controlled multicenter clinical study, which enrolled 67 patients with CAD who were treated with the sirolimus-eluting cobalt-chromium stent (Firebird 2 (TM), Microport Shanghai, Firebird 2 group), compared to another 49 patients treated with a bare cobalt alloy stent (Driver, Medtronic, control group). Continued 2-year clinical follow-up was performed after getting the initial 6-month angiographic and 1-year clinical follow-up. The incidence of major adverse cardiac events (MACE) including cardiac death, reinfarction and target lesion revascularization (TLR) and stent thrombosis were compared between the two groups.Results All patients in the Firebird 2 group (100.0%) and 48 patients in the control group (98.0%) completed the 2-year clinical follow-up. At the 1-year follow-up the use of the Firebird 2 stent was highly effective, resulting in a significant 94% decrease of TLR (26.5% in the control group and 1.5% in the Firebird 2 group, P<0.0001). A significant difference in TLR was maintained at 2-year follow-up, Firebird 2 group 1.5% and the control group 31.3% (P<0.0001). Between 1- and 2-year post-stenting, no more TLR occurred in the Firebird 2 group compared with two cases in the control group (P>0.05). There was a 1.5% incidence of MACE at 1- and 2-year follow-up in the Firebird 2 group, compared with 26.5% and 33.3% in the control group, respectively (all P<0.0001). The cumulative 1- and 2-year MACE free survival rates were 98.5% in the Firebird 2 group vs 73.5% and 66.7% in the control group (log rank P<0.0001). No case of stent thrombosis occurred during 2-year follow-up in the Firebird 2 group, compared with one case that suffered a definite stent thrombosis in the control group at 19-month post-stenting: this patient presented with unstable angina pectoris and was treated by balloon angioplasty.Conclusions Compared with the bare cobalt alloy stent, the Firebird 2 (TM) sirolimus-eluting cobalt-chromium stent is safe and effective in treating patients with CAD. The use of this stent was associated with a sustained clinical benefit and significantly lower rate of TLR and MACE up to 2 years post-stenting.

Six-month Clinical Outcomes of Firebird 2TM Sirolimus-Eluting Stent Implantation in Real-World Patients with Coronary Artery Diseases

Sirolimus-eluting Cobalt Alloyed Stents in Treating Patients with Coronary Artery Disease: Six-Month Angiographic and One-Year Clinical Follow-Up Result A Prospective, Historically Controlled, Multi-Center Clinical Study

Sirolimus-eluting Cobalt-Chromium Stents: Two-Year Clinical Results from First-in-man Study on the Firebird 2TM Stent

Long Term Efficacy and Safety of Chinese Made Sirolimus Eluting Stents: Results, Including off Label Usage, from Two Centres over Three Years

One-year Clinical Outcomes of Domestic Sirolimus-Eluting Stent in Treating Unselected Patients with Coronary Artery Disease

A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial

Firebird Sirolimus Eluting Stent Versus Bare Mental Stent in Patients with ST-segment Elevation Myocardial Infarction

Efficacy and Safety of Firebird Sirolimus-Eluting Stent in Treatment of Complex Coronary Lesions in Chinese Patients: One-Year Clinical and Eight-Month Angiographic Outcomes from the FIREMAN Registry.

Safety and Efficacy of the Cypher Select Sirolimus-Eluting Stent in the "real World" - Clinical and Angiographic Results from the China Cypher Select Registry

Safety and Efficacy of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Lesions: 12-Month Results from the TARGET II Trial.

The Clinical Application of FirebirdTM Drug Eluting Stent in Patients with Coronary Artery Disease

A randomized comparison of healing response of the BuMA Supreme stent and Xience stent at one- and two-month follow-up: PIONEER-II OCT randomized controlled trial.

Long-term Outcomes of Patients with Coronary Heart Disease Treated with Domestic Sirolimus-Eluting Partner Coronary Stent

Three‐year Clinical Outcomes of the Novel Sirolimus‐eluting Bioresorbable Scaffold for the Treatment of De Novo Coronary Artery Disease: A Prospective Patient‐level Pooled Analysis of NeoVas Trials

Long-term Performance of the Second-Generation Cobalt-Chromium Sirolimus-Eluting Stents in Real-World Clinical Practice: 3-Year Clinical Outcomes from the Prospective Multicenter FOCUS Registry

Study of long-term safety and efficacy of domestic Firebird rapamycin-eluting stent

Clinical effects of Firebird stent and Yinyi stent implantation in patients with coronary heart disease and diabetes

AS-152: Clinical Outcomes of Patients with ST-Elevated Myocardial Infarction Treated with 3 Types of Sirolimus-Eluting Stents: 1-Year Follow-Up Results

Clinical analysis of stent thrombosis after implantation of domestic cobalt-chromium drug-eluting stents

Real-World Use of the Second-Generation Cobalt-Chromium Sirolimus-Eluting Stents: 12-Month Results from the Prospective Multicentre Focus Registry

Safety and Efficacy of the Sirolimus-Eluting Stent in the Treatment of Patients with Lesions in Small Native Coronary Arteries